Press Releases 2019

  • Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on long fibrosis at the 2019 ATS conference

    Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on long fibrosis at the 2019 ATS conference

    Prometic today announced the presentation of three scientific posters on the Company’s lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™.

    Read Article
  • Prometic announces terms of equity rights offering

    Prometic announces terms of equity rights offering

    Prometic is pleased to confirm the terms of its previously announced equity rights offering for gross proceeds of up to $75,000,000.

    Read Article
  • Prometic reports its 2019 first quarter financial results

    Prometic reports its 2019 first quarter financial results

    We made excellent progress during the quarter towards completing the necessary development work to permit re-filing of our Ryplazim™ (plasminogen) (“RyplazimTM ”) BLA before the end of 2019

    Read Article
  • Prometic strengthens its leadership with a new management structure and the appointment of three new directors

    Prometic strengthens its leadership with a new management structure and the appointment of three new directors

    Prometic is pleased to announce today a new management structure to provide leadership to the Corporation and the appointment of Dr. Gary Bridger, Mr. Timothy Wach and Mr. Neil Klompas to the Board.

    Read Article
  • Prometic Completes Refinancing Transactions Including C$75 Million

    Prometic Completes Refinancing Transactions Including C$75 Million

    Prometic is also pleased to announce Kenneth Galbraith as Chief Executive Officer.

    Read Article
  • Prometic announces refinancing transactions

    Prometic announces refinancing transactions

    Prometic announced today its intention to enter into a series of related arrangements to restructure Prometic’s outstanding indebtedness, reduce its interest and certain other payment obligations.

    Read Article
  • Prometic reports fourth quarter and 2018 year-end financial results

    Prometic reports fourth quarter and 2018 year-end financial results

    Total revenues for 2018 of $47.4 million compared to $39.1 million in 2017 and significant increase in bioseparation 2018 revenues to $22.7 million, a 35% increase over 2017

    Read Article
  • Prometic to report its fourth quarter and 2018 year-end financial results and hold conference call / webcast

    Prometic to report its fourth quarter and 2018 year-end financial results and hold conference call / webcast

    Prometic announced today that it will report its financial results for the fourth quarter and year ended December 31, 2018 on Monday April 1, 2019 after market close.

    Read Article
  • Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP

    Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP

    Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP

    Read Article
  • Prometic secures additional USD $10 million (CAD $13.2 million) tranche from structured Alpha LP, an affiliate of Thomvest asset management

    Prometic secures additional USD $10 million (CAD $13.2 million) tranche from structured Alpha LP, an affiliate of Thomvest asset management

    Prometic announced today that it has secured an additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP (“SALP”), an affiliate of Thomvest Asset Management Inc.

    Read Article
  • Prometic retains investment bank for strategic transactions

    Prometic retains investment bank for strategic transactions

    Prometic announced that it has engaged Lazard to review and execute key strategic transactions for the Corporation.

    Read Article
  • loading
    Loading More...